PT  - JOURNAL ARTICLE
AU  - Nersesjan, Vardan
AU  - Amiri, Moshgan
AU  - Christensen, Hanne
AU  - Benros, Michael E.
AU  - Kondziella, Daniel
TI  - 30-day mortality and morbidity in COVID-19 versus influenza: A population- based study
AID  - 10.1101/2020.07.25.20162156
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.25.20162156
4099  - http://medrxiv.org/content/early/2020/07/28/2020.07.25.20162156.short
4100  - http://medrxiv.org/content/early/2020/07/28/2020.07.25.20162156.full
AB  - Background As of July 2020, COVID-19 has caused 500,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to influenza and individuals tested negative for COVID-19 are lacking. We aimed to investigate COVID-19 30-day mortality and new-onset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza.Methods and findings This population-based cohort study utilized electronic health records covering roughly half (n=2,647,229) of Denmark’s population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza were followed from November 1, 2017 to June 30, 2020. The main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza. In total, 224,639 individuals were tested for COVID-19. Among inpatients positive for COVID-19, 356 of 1657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p<0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to influenza and COVID-19-negative patients, respectively (all p<0.001). Compared to hospitalized patients with influenza, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p<0.05).Conclusions In this population-based study comparing COVID-19 with influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality, which is likely even higher than the stated 3.0 to 5.5-fold increase owing to more extensive testing for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received funding from Lundbeckfonden (grant number R349-2020-658 and R268-2016-3925), RH Forskningspulje (R143-A6132-B3632), Region Hovedstadens Forskningsfond til Sundhedsforskning 2019 (A6597), Savvaerksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat (27062019), and Offerfonden (F-23101-04).The sponsor had no role in the acquisition of the data, interpretation of the results or the decision to publish the findings. Conflict of Interest Disclosures: The authors have no relevant financial disclosuresAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Capital Region of Denmark waives approval for register-based studies on aggregated anonymized data (Section 14.2 of the Committee Act. 2; http://www.nvk.dk/english). Use of anonymized aggregate-level data was approved by the Danish Data Protection Agency. Results from ≤5 patients were displayed as '≤5' to ensure data privacyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be made available upon reasonable request